Peter S. Pang

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Alexandre Mebazaa, Beth A. Davison, Ovidiu Chioncel et al. · The Lancet · 2022 · 1K citations · Full text

Medicine, Cardiology, Internal Medicine +10

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

John R. Teerlink, Gad Cotter, Beth A. Davison et al. · The Lancet · 2012 · 908 citations

Medicine, Cardiology, Pharmacology +11

Recognition and Initial Management of Fulminant Myocarditis

Robb D. Kociol, Leslie T. Cooper, James C. Fang et al. · Circulation · 2020 · 596 citations · Full text

Medicine, Cardiology, Surgery +15

Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial

Andrew P. Ambrosy, Peter S. Pang, Sadiya S. Khan et al. · European Heart Journal · 2013 · 572 citations · Full text

Medicine, Cardiology, Internal Medicine +10

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

Marco Metra, Gad Cotter, Beth A. Davison et al. · Journal of the American College of Cardiology · 2012 · 425 citations · Full text

Medicine, Pharmacology, Toxicology +11